Amicus bolsters rare disease gene therapy pipeline with expanded UPenn deal

Amicus has added three more rare disease gene therapy programs to its pipeline through an expansion of its deal with the University of Pennsylvania, with the option to add at least a dozen more. The company also proposed Wednesday to raise $150

Read the full 423 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE